1. Participation in another clinical study with an investigational product during the last 3 weeks

2. Concurrent enrollment in another clinical study unless it is an observational (non-interventional)

clinical study or during the follow-up period of an interventional study.

3. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment with the

exception of those mentioned in this protocol. Concurrent use of hormonal therapy for noncancer-

related conditions (e.g., hormone replacement therapy) is acceptable.

4. Lack of full recovery from a major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.

5. History of allogenic organ transplantation.

Abequolixron (RGX-104) and Durvalumab in Lung Cancer